Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03348670 · ClinicalTrials.gov registry record · Phase 2

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

A Phase 2 study of Prostate Cancer, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

Active
Registry status
Phase 2
Development phase
600
Enrollment target
1
Study location

NCT03348670 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 600 participants, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03348670, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. The study approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on China Import - abiraterone acetate tablet plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Abiraterone - Usual
  • DRUG Abiraterone - Study

Study Locations (1)

Maryland

  • Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701 - Rockville

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2023-08-18
Est. Completion 2026-05-28
Phase Phase 2

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03348670

The ClinicalTrials.gov registry entry for NCT03348670 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The listed sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abiraterone - Usual is the first listed.

NCT03348670 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03348670 about?

NCT03348670 is a clinical study titled "Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms". The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic eff...

What is the current status of trial NCT03348670?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2023-08-18. Estimated completion is 2026-05-28.

What conditions does trial NCT03348670 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03348670?

The interventions under investigation include: Abiraterone - Usual (DRUG), Abiraterone - Study (DRUG).

Who is sponsoring clinical trial NCT03348670?

This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03348670 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.